Evidence map›Paper›PMID 36399512›Full record

ArticlePLoS pathogens2022

The apparent interferon resistance of transmitted HIV-1 is possibly a consequence of enhanced replicative fitness.

Elena Sugrue, Arthur Wickenhagen, Nardus Mollentze, Muhamad Afiq Aziz, Vattipally B Sreenu, Sven Truxa, Lily Tong, Ana da Silva Filipe, David L Robertson, Joseph Hughes and 2 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 3 countries.

Elena SugrueMRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, United Kingdom.
Arthur WickenhagenMRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, United Kingdom.
Nardus MollentzeMRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, United Kingdom.
Muhamad Afiq AzizMRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, United Kingdom.
Vattipally B SreenuMRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, United Kingdom.
Sven TruxaMRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, United Kingdom.
Lily TongMRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, United Kingdom.
Ana da Silva FilipeMRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, United Kingdom.
David L RobertsonMRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, United Kingdom.
Joseph HughesMRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, United Kingdom.
Suzannah J RihnMRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, United Kingdom.
Sam J WilsonMRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow, United Kingdom.ORCID 0000-0002-6065-0895
MRC University of Glasgow Centre for Virus Research · GBGerman Cancer Research Center · DEUniversity of Malaya · MY

Funding

Medical Research Council MC_UU_12014/10Medical Research Council MC_UU_12014/12Medical Research Council MC_UU_12018/12Medical Research Council MR/P022642/1Medical Research Council MR/V01157X/1Wellcome Trust 201366/Z/16/Z
6 · The paper itself

Abstract

HIV-1 transmission via sexual exposure is an inefficient process. When transmission does occur, newly infected individuals are colonized by the descendants of either a single virion or a very small number of establishing virions. These transmitted founder (TF) viruses are more interferon (IFN)-resistant than chronic control (CC) viruses present 6 months after transmission. To identify the specific molecular defences that make CC viruses more susceptible to the IFN-induced 'antiviral state', we established a single pair of fluorescent TF and CC viruses and used arrayed interferon-stimulated gene (ISG) expression screening to identify candidate antiviral effectors. However, we observed a relatively uniform ISG resistance of transmitted HIV-1, and this directed us to investigate possible underlying mechanisms. Simple simulations, where we varied a single parameter, illustrated that reduced growth rate could possibly underly apparent interferon sensitivity. To examine this possibility, we closely monitored in vitro propagation of a model TF/CC pair (closely matched in replicative fitness) over a targeted range of IFN concentrations. Fitting standard four-parameter logistic growth models, in which experimental variables were regressed against growth rate and carrying capacity, to our in vitro growth curves, further highlighted that small differences in replicative growth rates could recapitulate our in vitro observations. We reasoned that if growth rate underlies apparent interferon resistance, transmitted HIV-1 would be similarly resistant to any growth rate inhibitor. Accordingly, we show that two transmitted founder HIV-1 viruses are relatively resistant to antiretroviral drugs, while their matched chronic control viruses were more sensitive. We propose that, when present, the apparent IFN resistance of transmitted HIV-1 could possibly be explained by enhanced replicative fitness, as opposed to specific resistance to individual IFN-induced defences. However, further work is required to establish how generalisable this mechanism of relative IFN resistance might be.

Indexed as

DermatitisHIV-1HIV SeropositivityAntiviral AgentsDNA ReplicationHumansInterferonsAntiviral AgentsInterferons

Identifiers

PMID36399512
PMCPMC9718408
OpenAlexW4309306162

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.